

The molecular diagnostic application that characterizes the complex mutational landscape of the major solid tumors by combining a capture-based target enrichment kit with the analytical performance and advanced features of the SOPHiA DDM™ platform.

Main Features

The CE-IVD marked SOPHiA Solid Tumor Solution covers **42 genes** associated with solid tumors, including lung, colorectal, skin, and brain cancers. It also covers 6 unique loci to detect MSI¹ status associated with colorectal cancer. Probe design is optimized to guarantee high on-target rate and coverage uniformity throughout the entire target regions.

Gene Panel	Variants Called	Recommendations	Wet Lab
<i>AKT1</i> (3), <i>ALK</i> (21-25), <i>BRAF</i> (11,15), <i>CDK4</i> (2), <i>CDKN2A</i> (1*,2,3), <i>CTNNB1</i> (3), <i>DDR2</i> (17), <i>DICER1</i> (24,25), <i>EGFR</i> (18-21), <i>ERBB2</i> (8,17,20), <i>ERBB4</i> (10,12), <i>FBXW7</i> (7-11), <i>FGFR1</i> (12,14), <i>FGFR2</i> (7,12,14), <i>FGFR3</i> (7,9,14,16), <i>FOXL2</i> (1*), <i>GNAI1</i> (4,5), <i>GNAQ</i> (4,5), <i>GNAS</i> (8), <i>H3F3A</i> (2*), <i>H3F3B</i> (2*), <i>HIST1H3B</i> (1), <i>HRAS</i> (2-4), <i>IDH1</i> (4), <i>IDH2</i> (4), <i>KIT</i> (8-11,13,17,18), <i>KRAS</i> (2-4), <i>MAP2K1</i> (2,3), <i>MET</i> (2,14-20), <i>MYOD1</i> (1), <i>NRAS</i> (2-4), <i>PDGFRA</i> (12,14,18), <i>PIK3CA</i> (2*,3,6*,8,10,21), <i>PTPN11</i> (3), <i>RAC1</i> (3), <i>RAF1</i> (7,10,12,13*,14*,15*), <i>RET</i> (11,13,15,16), <i>ROS1</i> (38*,41*), <i>SF3B1</i> (15-17), <i>SMAD4</i> (8-12), <i>TERT</i> (promoter*,1*,8*,9*,13*), <i>TP53</i> (2-11)	<ul style="list-style-type: none"> • SNVs and Indels in all genes of the panel • <i>MET</i> large deletions • <i>TERT</i> promoter mutations C228T and C250T • MSI¹ status in 6 unique loci associated with colorectal cancer: BAT-25, BAT-26, CAT-25, NR-21, NR-22 and NR-27 • Gene amplification events in 24 genes: <i>ALK</i>, <i>BRAF</i>, <i>CDK4</i>, <i>CDKN2A</i>, <i>EGFR</i>, <i>ERBB2</i>, <i>FBXW7</i>, <i>FGFR1</i>, <i>FGFR2</i>, <i>FGFR3</i>, <i>HRAS</i>, <i>KIT</i>, <i>KRAS</i>, <i>MET</i>, <i>MYOD1</i>, <i>NRAS</i>, <i>PDGFRA</i>, <i>PIK3CA</i>, <i>RAF1</i>, <i>ROS1</i>, <i>RET</i>, <i>SF3B1</i>, <i>TERT</i> and <i>TP53</i> 	<p>Starting material ≥10 ng (50 ng recommended)</p> <p>Sample type FFPE, fresh-frozen tissue</p> <p>Samples per run for 1000x coverage depth / Sequencer (Flow Cell/Ion Chip Kit)² 8 / Illumina MiniSeq™ Mid Output Kit (2x150) 24 / Illumina MiSeq® v3 (2x300bp)* 12 / Ion Torrent™ Ion S5 System (Ion 530™)</p>	<p>Day 1: Library Preparation</p> <p>Day 2: Capture and Sequencing</p> <p>Total library preparation time: 1.5 days</p>

*Hotspots only ²x150-cycle sequencing run (paired-end) is recommended

Analytical Performance

The SOPHiA DDM™ platform analyzes complex NGS data by detecting, annotating and pre-classifying multiple types of genomic alterations in one unique experiment. The platform reaches clinical grade-performance.

Analysis time from FASTQ: from ≥ 4 hours³

	Observed (%)	Lower 95% CI
Sensitivity	98.77	93.31
Specificity	100	99.92
Accuracy	99.97	99.85
Precision	100	96.25
Repeatability	96.45	96.41
Reproducibility	89.13	89.05
Coverage uniformity	98.70	92.50*

Performance values have been calculated based on SNVs and Indels only in 150 samples processed on Illumina MiSeq® using KAPA™ HyperPlus KK8512 library preparation reagents.
*5% quantile

One Simple Intuitive Platform: Beyond Analytics

Accelerated assessment and reporting of genomic variants

The platform helps users to immediately focus on relevant genomic alterations. Several features facilitate their interpretation process:

- Hotspot screening
- Algorithm-supported variant pre-classification
- Fully customizable filters
- Comprehensive report

Confident decision-making

The SOPHiA DDM™ platform integrates the OncoPortal™. This feature provides the latest scientific evidence on the significance of each genomic alteration to support informed decision-making for research purposes.

Global support at every step

We offer local support anywhere in the world. Our dedicated bioinformaticians help save time and resources, ensuring fast resolution of workflow disruptions. In addition, our Set Up Program provides assistance with assay set up for fast and worry-free transition to routine testing.

Secure and unlimited data storage

The SOPHiA DDM™ platform provides unlimited and unrestricted storage, while keeping data safe by applying the highest industrial standards of encryption in compliance with local data security policies.

Access to the SOPHiA GENETICS community

Through the SOPHiA DDM™ platform genomics experts from hundreds of healthcare institutions interpret their findings and flag the pathogenicity level of variants. This highly valuable information enriches the variant knowledge base and is safely shared among the members of the community, supporting their decision-making process for research purposes.

1. MSI: Microsatellite Instability
2. Sequencing recommendations and specifications for other sequencing kits and instruments available upon request. Delivery time may vary according to the selected sequencing platform.
3. Analysis time may vary depending on the number of samples multiplexed and server load.

This CE IVD-marked product is For In Vitro Diagnostic Use in Europe, Turkey and Israel markets. This product has not been cleared and approved by the U.S. FDA and may not be approved in some countries/regions. Please contact SOPHiA GENETICS local Sales representatives to obtain the appropriate product information for your country of residence.

All third party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS' use of third party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third party trademarks is to identify the corresponding third party goods and/or services and shall be considered nominative fair use under the trademark law.